Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Marie Skłodowska-Curie Action · Running

TTRAIL Transferable Trustworthy Radiotherapy with Artificial Intelligence

Coordinator
Universite De Rennes, France
Runs
1 March 2027 to 28 February 2031
Status
Running
EU funding
€4.7m
Total cost
—
Partners
24 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101312626

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer is the leading cause of death in Europe and the second worldwide. Over 50% of patients are treated with Radiotherapy (RT) and it accounts for 40% of cures, yet recurrence and toxicities remain significant challenges. Despite major advances in imaging, planning and delivery, RT still largely follows a “one-dose-fits-all” approach, leading to variable outcomes, toxicities and limited adaptability to patient-specific biology.

Europe is currently undergoing a digital transformation driven by AI, advanced imaging and the European Health Data Space, but current AI solutions in RT remain fragmented, poorly generalizable and insufficiently explainable, preventing their safe deployment in clinical practice. TTRAIL aims at improving the safety, precision and personalization of radiotherapy (RT) by training 15 Doctoral Candidates as the first generation of Translational AI Radiotherapy Scientists, capable of uniting AI innovation with clinical radiotherapy, medical physics, regulatory science and digital-health translation.

Their training will span multiscale data integration, uncertainty quantification, explainable and causal outcome modelling, digital twins and real-time adaptive dose delivery, aligned with the EU AI Act. The consortium unites top European universities, engineering schools, cancer centers and major industrial partners, providing access to cutting-edge RT platforms, large multicentre datasets and expertise across AI, imaging, oncology, physics and regulatory compliance.

This intersectoral ecosystem ensures robust scientific training, clinical immersion, industrial exposure and strong open-science practices. By delivering a fully integrated, trust-by-design framework for AI-enabled Adaptive Radiotherapy, TTRAIL will produce highly skilled researchers able to lead the future of personalised, safe and explainable cancer treatment in Europe.

Topics

Who is involved

OrganisationCityCountryRole
Universite De RennesRennesFranceCoordinator
Universitaet BernBernSwitzerlandParticipant
Instituto Tecnologico MetropolitanoMedellinCOAssociatedpartner
Brainlab SeMunchenGermanyAssociatedpartner
Karlsruher Institut Fuer TechnologieKarlsruheGermanyParticipant
Panepistimio PatronRio PatrasGreeceParticipant
Empresa De Base Tecnologica Internacional De Canarias, Sociedad LimitadaLas Palmas De Gran CanariaSpainAssociatedpartner
Idcq Hospitales Y Sanidad SLMadridSpainAssociatedpartner
Siemens Healthcare SLMadridSpainAssociatedpartner
Universidad Carlos Iii De MadridGetafe (Madrid)SpainParticipant
Universidad Rey Juan CarlosMostolesSpainParticipant
Centre Hospitalier Regional Et Universitaire De BrestBrestFranceAssociatedpartner
Centre Eugène MarquisRennesFranceAssociatedpartner
Dassault SystemesVelizy VillacoublayFranceAssociatedpartner
Ecole Centrale De NantesNantes Cedex 3FranceParticipant
Eurecom GieBiotFranceParticipant
Institut Mines-TelecomPalaiseauFranceParticipant
Sorbonne UniversiteParisFranceAssociatedpartner
UnicancerParisFranceAssociatedpartner
Fondazione Irccs Istituto Nazionale Dei TumoriMilanItalyParticipant
Ospedale San Raffaele SRLMilanoItalyAssociatedpartner
Politecnico Di MilanoMilanoItalyAssociatedpartner
Kiwa Nederland BVApeldoornNetherlandsAssociatedpartner
The University of ManchesterManchesterUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI